NEW YORK (GenomeWeb News) – EraGen Biosciences said today that it has formed a strategic partnership with Illumina to develop high-throughput, multiplexed clinical assays.

Under the agreement, EraGen, based in Madison, Wis., has non-exclusively licensed the use of Illumina's BeadXpress platform to develop and commercialize molecular-based, high-throughput, clinical assays using EraGen's MultiCode-PLx technology.

Meantime, Illumina has non-exclusively licensed EraGen's MultiCode-PLx technology for the life sciences, research, and clinical markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.